NuvOx Announces MHRA Approval to Commence Phase IIb Stroke Trial

Tucson, AZ, February 14, 2025 –(PR.com)– NuvOx Therapeutics, Inc. (“NuvOx”) announced that The Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom in collaboration with the Research Ethics Committee has accepted the amended request for a clinical trial authorisation (CTA). This acceptance will enable the company to commence the Phase IIb NOVEL trial (NanO2 in Large VessEL Occlusion Stroke (NOVEL): a multicentre single-blind, randomised, placebo-controlled blinded biomarker end-point clinical trial of perfluorocarbon in acute ischaemic stroke due to large vessel occlusion (LVO).Continue reading

The Stephenson Global Pancreatic Cancer Research Institute Launches First-of-Its-Kind Global Scientific Awards to Advance Breakthrough Discovery in Pancreatic Cancer

  • Stephenson Global Prize opportunity invites top scientific minds for one of the largest privately funded rewards — Call for Nominations open now through March 14.
  • Stephenson Global Scholar Grants seek the most innovative solutions to tackle the challenges of pancreatic cancer — Grant Applications open now through March 14.

Continue reading

TGen appoints Dr. Aleksandar Sekulic as Physician-in-Chief

The Translational Genomics Research Institute (TGen), part of City of Hope, today announced the appointment of Aleksandar Sekulic, M.D., Ph.D., a distinguished physician-scientist known for his work in skin cancer treatment and clinical research, as Physician-in-Chief. Dr. Sekulic specializes in immunotherapy and targeted therapies for a range of skin cancers, from melanoma to rare types of cutaneous lymphoma and epidermal neoplasms. His patient care approach integrates advanced treatments with a focus on individual needs, ensuring comprehensive, whole-person care.Continue reading